Q3 Financial Results 2025-26

RNS Number : 4597J

Beximco Pharmaceuticals PLC

24 June 2026

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

BEXIMCO PHARMACEUTICALS PLC.

Q3 Financial Results 2025-26

Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients today announces its unaudited financial results for the third quarter and nine months ended 31 March 2026.

Financial Highlights (Consolidated)

Nine months ended 31 March 2026

· Net sales increased 13.1% to Bangladesh Taka ("BDT") 41,428.0m / £256.9m (2024-25: BDT 36,622.0m / £235.0m)

o Domestic sales increased 14.4% to BDT 38,459.2m / £238.5m (2024-25: BDT 33,617.7m / £215.7m)

o Export sales decreased 1.2% to BDT 2,968.8m / £18.4m (2024-25: BDT 3,004.3m / £19.3m)

· Profit after tax increased 34.0% to BDT 7,048.6m / £43.7m (2024-25: BDT 5,261.0m / £33.8m)

Third-quarter ended 31 March 2026

· Net sales increased 8.1% to BDT 13,627.8m / £84.5m (2024-25: BDT 12,608.6m / £80.9m)

· Profit after tax increased 30.6% to BDT 2,254.4m / £14.0m (2024-25: BDT 1,726.0m / £11.1m)

The detailed accounts can be viewed at the Company website: www.beximcopharma.com

For a summary of financial and operational highlights for the period from 1 January 2025 to 31 March 2026, please refer to the previous announcement titled: "Financial Results for the Periods from 1 January 2025 to 31 March 2026", released today.

(Exchange rates of £1=Taka 161.2895 for 31 March 2026 and £1=Taka 155.8649 for 31 March 2025 have been used in this announcement.)

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext. 20111

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext. 20030

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Tel: +880 2 41060531, Ext. 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0)20 3368 3551 / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

FTI Consulting

Simon Conway / Sam Purewal / Lucy Molloy

Tel: +44 (0)20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals PLC.

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of financial position (Un-audited)

As at March 31, 2026

	March 31, 2026	Taka '000 June 30, 2025
ASSETS

Non-current assets	50,664,655	49,461,242
Property, plant and equipment	44,822,991	43,541,872
Right-of-use assets	423,012	485,613
Intangible assets	4,689,328	4,694,134
Deferred tax asset	33,780	44,079
Goodwill	674,570	674,570
Other investments	20,974	20,974

Current assets	28,066,596	23,786,005
Inventories	14,225,662	13,586,476
Spares and supplies	966,481	799,644
Trade and other receivables	3,768,406	3,628,788
Loans, advances, deposits and prepayments	3,528,252	2,814,492
Advance income tax	400,152	356,508
Short term investment	950,000	900,000
Cash and cash equivalents	4,227,643	1,700,097

TOTAL ASSETS	78,731,251	73,247,247

EQUITY AND LIABILITIES
Equity attributable to the owners of the company	60,048,483	53,107,137
Share capital	4,461,121	4,461,121
Share premium	5,269,475	5,269,475
Excess of issue price over face value of GDRs	1,689,637	1,689,637
Capital reserve on merger	294,951	294,951
Revaluation surplus	1,131,583	1,133,870
Unrealized gain/(loss)	18,149	18,149
Retained earnings	47,183,567	40,239,934

Non-controlling interest	4,047,682	3,977,499

TOTAL EQUITY	64,096,165	57,084,636

Non-current liabilities	7,831,707	7,769,471
Long term borrowings-net of current maturity	1,298,330	1,503,595
Liability for gratuity, pension and WPPF	3,951,697	3,690,096
Deferred tax liability	2,581,680	2,575,780

Current liabilities	6,803,379	8,393,140
Short term borrowings	973,567	2,025,394
Long term borrowings-current maturity	891,550	1,436,752
Trade and other payables	2,124,152	2,925,994
Accrued expenses	1,394,433	1,174,096
Dividend payable	137,932	302,272
Income tax payable	1,281,745	528,632
TOTAL LIABILITIES	14,635,086	16,162,611
TOTAL EQUITY AND LIABILITIES	78,731,251	73,247,247

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of profit or loss and other comprehensive income (Un-audited)

For the period July 2025- March 2026

				Taka '000

	July 2025 - March 2026	July 2024 - March 2025	January - March 2026	January - March 2025

Net revenue	41,427,963	36,621,960	13,627,807	12,608,553
Cost of goods sold	(21,118,060)	(19,822,775)	(6,931,325)	(6,787,928)

Gross profit	20,309,903	16,799,185	6,696,482	5,820,625

Operating expenses	(10,737,944)	(9,288,133)	(3,687,910)	(3,397,216)
General and administrative expenses	(1,133,559)	(1,026,632)	(381,590)	(338,255)
Selling, marketing and distribution expenses	(9,604,385)	(8,261,501)	(3,306,320)	(3,058,961)
Profit from operations	9,571,959	7,511,052	3,008,572	2,423,409

Other income	566,312	481,900	193,267	255,344
Finance cost	(519,609)	(802,608)	(146,061)	(314,630)
Profit before tax and WPPF	9,618,662	7,190,344	3,055,778	2,364,123
Contribution to WPPF	(467,208)	(351,606)	(148,998)	(116,347)
Profit before tax	9,151,454	6,838,738	2,906,780	2,247,776
Income tax expenses	(2,102,822)	(1,577,731)	(652,351)	(521,780)
Current tax	(2,085,959)	(1,580,974)	(651,677)	(517,572)
Deferred tax	(16,863)	3,243	(674)	(4,208)
Profit after tax	7,048,632	5,261,007	2,254,429	1,725,996

Profit/(loss) attributable to:
Owners of the Company	6,940,682	5,231,738	2,219,926	1,721,356
Non-controlling interest	107,950	29,269	34,503	4,640
	7,048,632	5,261,007	2,254,429	1,725,996
Other comprehensive income/(loss)	-	1	-	-
Total comprehensive income	7,048,632	5,261,008	2,254,429	1,725,996

Total comprehensive income attributable to:
Owners of the Company	6,940,682	5,231,739	2,219,926	1,721,356
Non-controlling interest	107,950	29,269	34,503	4,640
	7,048,632	5,261,008	2,254,429	1,725,996

Earnings per share (EPS)	15.56	11.73	4.98	3.86

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of changes in equity (Un-audited)

For the period July 2025-March 2026

Taka '000

		Share capital		Share premium	Excess of issue price over face value of GDRs			Capital reserve on merger		Revaluation surplus		Unrealized gain/(loss)		Retained earnings		Equity attributable to owners of the company		Non-controlling interest		Total equity
Balance as on July 01, 2025		4,461,121		5,269,475	1,689,637			294,951		1,133,870		18,149		40,239,934		53,107,137		3,977,499		57,084,636
Total comprehensive income:
Profit/(loss) for the period		-		-	-			-		-		-		6,940,682		6,940,682		107,950		7,048,632
Other comprehensive income/(loss)		-		-	-			-		-		-		-		-		-		-
Transactions with the shareholders:
Cash dividend		-		-	-			-		-		-		-		-		(37,767)		(37,767)
Others:
Adjustment for depreciation on revalued assets		-		-	-			-		(2,951)		-		2,951		-		-		-
Adjustment for deferred tax on revalued assets		-		-	-			-		664		-		-		664		-		664
Balance as on March 31, 2026		4,461,121		5,269,475	1,689,637			294,951		1,131,583		18,149		47,183,567		60,048,483		4,047,682		64,096,165
Net asset value (NAV) per share														Tk.		134.60
	Share capital		Share premium			Excess of issue price over face value of GDRs	Capital reserve on merger		Revaluation surplus		Unrealized gain/(loss)		Retained earnings		Equity attributable to owners of the company		Non-controlling interest		Total equity
Balance as on July 01, 2024	4,461,121		5,269,475			1,689,637	294,951		1,137,306		18,148		35,079,327		47,949,965		3,952,938		51,902,903
Total comprehensive income:
Profit/(loss) for the period	-		-			-	-		-		-		5,231,738		5,231,738		29,269		5,261,007
Other comprehensive income/(loss)	-		-			-	-		-		1		-		1		-		1
Transactions with the shareholders:
Cash dividend	-		-			-	-		-		-		(1,784,448)		(1,784,448)		(33,687)		(1,818,135)
Others:
Adjustment for depreciation on revalued assets	-		-			-	-		(3,325)		-		3,325		-		-		-
Adjustment for deferred tax on revalued assets	-		-			-	-		748		-		-		748		-		748
Balance as on March 31, 2025	4,461,121		5,269,475			1,689,637	294,951		1,134,729		18,149		38,529,942		51,398,004		3,948,520		55,346,524
Net asset value (NAV) per share													Tk.		115.21

For the period July 2024-March 2025

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of cash flows (Un-audited)

For the period July 2025-March 2026

	July 2025 - March 2026	Taka '000 July 2024 - March 2025
Cash flows from operating activities

Cash receipts from customers and others	41,636,365	36,394,207
Cash paid to suppliers and employees	(32,436,664)	(30,100,181)
Cash generated from operations	9,199,701	6,294,026

Interest paid	(531,937)	(769,431)
Interest received	174,786	18,479
Income tax paid	(1,376,492)	(1,322,242)
Net cash generated from operating activities	7,466,058	4,220,832

Cash flows from investing activities
Acquisition of property, plant and equipment	(2,664,525)	(2,220,342)
Intangible assets	(282,825)	(164,411)
Disposal of property, plant and equipment	11,353	40,123
Disposal of intangible assets	18,255	-
Dividend received	1,256	975
Short term investment	(50,000)	(700,000)
Net cash used in investing activities	(2,966,486)	(3,043,655)

Cash flows from financing activities

Net increase/(decrease) in long term borrowings	(717,564)	47,161
Net increase/(decrease) in short term borrowings	(1,051,826)	1,390,117
Dividend paid	(202,106)	(1,593,640)
Net cash from/(used in) financing activities	(1,971,496)	(156,362)
Increase/(decrease) in cash and cash equivalents	2,528,076	1,020,815
Opening cash and cash equivalents	1,700,097	854,106
Effect of exchange rate changes on cash and cash equivalents	(530)	8,179
Closing cash and cash equivalents	4,227,643	1,883,100

Net operating cash flows per share	16.74	9.46

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

QRTSESFMDEMSELM

Date	24 Jun 2026
Time	07:04:00
Category	Results
ID	4597J

Date	24 Jun 2026
Time	07:04:00
Category	Results
ID	4597J

t

Company Information

AI Summary

RNS Metadata

Company Information

AI Summary

RNS Metadata

Q3 Financial Results 2025-26